Apogee Therapeutics, Common Stock Performance
| APGE Stock | 40.14 0.25 0.63% |
The firm shows a Beta (market volatility) of 1.32, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Apogee Therapeutics, will likely underperform. At this point, Apogee Therapeutics, has a negative expected return of -0.17%. Please make sure to confirm Apogee Therapeutics,'s maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Apogee Therapeutics, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Apogee Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (2.33) | Five Day Return 0.0502 | Year To Date Return (15.40) | Ten Year Return 87.89 | All Time Return 87.89 |
1 | Disposition of 1360 shares by Dambkowski Carl of Apogee Therapeutics, at 22.86 subject to Rule 16b-3 | 01/02/2025 |
2 | Apogee Therapeutics chief medical officer sells shares worth 191,7 - Investing.com | 01/03/2025 |
3 | Disposition of 2868 shares by Henderson Michael Thomas of Apogee Therapeutics, at 49.38 subject to Rule 16b-3 | 01/08/2025 |
4 | Disposition of 100 shares by Dambkowski Carl of Apogee Therapeutics, at 47.92 subject to Rule 16b-3 | 01/17/2025 |
5 | Disposition of 8500 shares by Henderson Michael Thomas of Apogee Therapeutics, at 22.86 subject to Rule 16b-3 | 01/31/2025 |
6 | Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis | 02/03/2025 |
7 | Disposition of 15000 shares by Henderson Michael Thomas of Apogee Therapeutics, at 40.58 subject to Rule 16b-3 | 02/05/2025 |
8 | Apogee Therapeutics Inc Announces Participation in Upcoming Investor Conferences | 02/25/2025 |
9 | Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy ... | 02/28/2025 |
10 | Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and S... | 03/03/2025 |
11 | Apogee Therapeutics Posts Quarterly Earnings Results, Misses Estimates By 0.25 EPS | 03/04/2025 |
12 | Disposition of 2674 shares by Henderson Michael Thomas of Apogee Therapeutics, at 30.62 subject to Rule 16b-3 | 03/05/2025 |
13 | Disposition of 1590 shares by Dambkowski Carl of Apogee Therapeutics, at 30.48 subject to Rule 16b-3 | 03/07/2025 |
| Begin Period Cash Flow | 118.6 M |
Apogee |
Apogee Therapeutics, Relative Risk vs. Return Landscape
If you would invest 4,718 in Apogee Therapeutics, Common on December 26, 2024 and sell it today you would lose (703.00) from holding Apogee Therapeutics, Common or give up 14.9% of portfolio value over 90 days. Apogee Therapeutics, Common is currently does not generate positive expected returns and assumes 4.3782% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Apogee, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Apogee Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apogee Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apogee Therapeutics, Common, and traders can use it to determine the average amount a Apogee Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0381
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | APGE |
Estimated Market Risk
| 4.38 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Apogee Therapeutics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apogee Therapeutics, by adding Apogee Therapeutics, to a well-diversified portfolio.
Apogee Therapeutics, Fundamentals Growth
Apogee Stock prices reflect investors' perceptions of the future prospects and financial health of Apogee Therapeutics,, and Apogee Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apogee Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.86 B | ||||
| Shares Outstanding | 44.6 M | ||||
| Price To Book | 3.31 X | ||||
| EBITDA | (216.87 M) | ||||
| Net Income | (182.15 M) | ||||
| Total Debt | 11.83 M | ||||
| Book Value Per Share | 12.35 X | ||||
| Cash Flow From Operations | (171.17 M) | ||||
| Earnings Per Share | (3.30) X | ||||
| Market Capitalization | 2.32 B | ||||
| Total Asset | 753.95 M | ||||
| Retained Earnings | (305.92 M) | ||||
| Working Capital | 501.15 M | ||||
About Apogee Therapeutics, Performance
By analyzing Apogee Therapeutics,'s fundamental ratios, stakeholders can gain valuable insights into Apogee Therapeutics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Apogee Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Apogee Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.20) | (0.21) |
Things to note about Apogee Therapeutics, performance evaluation
Checking the ongoing alerts about Apogee Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apogee Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apogee Therapeutics, generated a negative expected return over the last 90 days | |
| Apogee Therapeutics, has high historical volatility and very poor performance | |
| Apogee Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (182.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Apogee Therapeutics, generates negative cash flow from operations | |
| Apogee Therapeutics, has a very weak financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Disposition of 1590 shares by Dambkowski Carl of Apogee Therapeutics, at 30.48 subject to Rule 16b-3 |
- Analyzing Apogee Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apogee Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Apogee Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apogee Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apogee Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apogee Therapeutics,'s stock. These opinions can provide insight into Apogee Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Apogee Stock analysis
When running Apogee Therapeutics,'s price analysis, check to measure Apogee Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apogee Therapeutics, is operating at the current time. Most of Apogee Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Apogee Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apogee Therapeutics,'s price. Additionally, you may evaluate how the addition of Apogee Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |